Aralast NP is a prescription drug approved by the Food and Drug Administration (FDA) as maintenance therapy in adults who have clinically evident emphysema due to Alpha-1 antitrypsin (AAT) deficiency, a rare genetic condition. Aralast NP is also known by its drug name, alpha1-proteinase inhibitor [human].
Aralast NP is an alpha1-proteinase inhibitor, a type of molecule derived from human plasma. Aralast NP is believed to work by protecting the lungs from damage.
How do I take it?
Aralast NP is administered once a week as an intravenous infusion.
Aralast NP comes in vial form and requires reconstitution.
The FDA-approved label for Aralast NP lists common side effects including headache, fatigue, runny nose, muscle and joint discomfort, and injection site reactions.
Rare but serious side effects listed for Aralast NP can include severe allergic reactions and the potential risk for transmitting infectious agents such as viruses.
For more details about this treatment, visit:
Aralast NP – RxList